Sun Pharmaceutical Industries announced that the company has entered into a definitive agreement to acquire Pola Pharma Inc. (Pola Pharma), a Japanese pharmaceutical company engaged in research and development, manufacture, sale and distribution of branded and generic products in Japan. The portfolio of Pola Pharma primarily comprises dermatology products. The announcement was made after market hours yesterday, 26 November 2018.
Nava Bharat Ventures and its subsidiary (Nava Bharat Energy (India)) signed contracts with Tata Power Trading for power supply of 25 MW and 100 MW respectively to Telangana State Grid. The contracts commence from 15 January 2019 to 30 April 2019 and are at a net price of Rs 5.75 per unit. The announcement was made after market hours yesterday, 26 November 2018.
Unichem Laboratories received EIR for post marketing adverse drug experience inspection conducted by the USFDA from June 25-29, indicating closure of inspection. The announcement was made after market hours yesterday, 26 November 2018.
IFCI said that on account of resolution of Binani Cement through NCLT, IFCI, which is holding 42,16,850 security receipts of the face value of Rs 1000 each has received an amount of Rs 491.84 crore, net of TDS of Rs 30.55 crore. The announcement was made after market hours yesterday, 26 November 2018.
GIC Housing Finance's net profit fell 1.01% to Rs 46.20 crore on 11.9% rise in total income to Rs 301.53 crore in Q2 September 2018 over Q2 September 2017. The announcement was made after market hours yesterday, 26 November 2018.
0 thoughts on “Sun Pharma in focus on plan to acquire Pola Pharma”